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OVERVIEW — This background paper provides an overview of the HIV/
AIDS epidemic in the United States and discusses how treatment of the
disease and the populations most affected by it have changed over time.
The federal government’s domestic and global efforts in prevention, re-
search, and treatment of the disease are highlighted. The paper outlines
the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act,
a set of programs that fund treatment services for uninsured and
underinsured individuals living with HIV/AIDS, and places it in the
context of other federal programs that fund treatment for HIV/AIDS.
Policy issues for Ryan White’s potential congressional reauthorization
are also discussed.
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Caring for “Ryan White”:
The Fundamentals of
HIV/AIDS Treatment Policy
Twenty-five years ago, becoming infected with HIV (human immunodefi-
ciency virus) was considered a death sentence. There was little the medical
establishment could do but comfort a patient with HIV as the virus repli-
cated in the body unchecked, completely destroying the immune system
and ultimately resulting in diagnosis with AIDS (acquired immunodefi-
ciency syndrome). Death followed months of progressive weakening and
wasting, often preceded by blindness and/or dementia. Tens of thousands
died this way before remarkable treatments were discovered in the mid
1990s. Those discoveries have transformed HIV/AIDS from a terminal ill-
ness to a chronic condition. People who are able to receive treatment are
able to live long, productive lives.
Still, after two decades of gathering knowledge about the cause of the
disease and a decade after the life-extending drugs became available, AIDS
is the number one killer of African American women aged 25 to 34 in the
United States, and the number of new infections each year has not abated.
What began as a disease mostly transmitted by men who have sex with
men has become one that increasingly affects heterosexual populations
and reaches the most vulnerable segments of American society: the low-
income, the uninsured, and racial and ethnic minority populations. The
increasing HIV/AIDS disease burden borne by vulnerable populations
in this country makes it ever more important to consider the viability of
funding sources for treatment.
Although Medicaid is the largest funder of care for low-income people with
HIV/AIDS, the Ryan White Comprehensive AIDS Resources Emergency
(CARE) Act, known simply as “Ryan White,” funds treatment for those
who are not eligible for Medicaid but are low-income and uninsured or
underinsured. The Act was named in honor of Ryan White, a hemophiliac
who contracted HIV from a blood transfusion and faced tremendous dis-
crimination due to others’ fear and lack of understanding of his disease.
The Act was originally authorized in 1990, the year he died, and was reau-
thorized in 1996 and 2000; the current authorization is set to expire on Sep-
tember 30, 2005. The program has grown increasingly complex through
each reauthorization, reflecting scientists’ evolving understanding of the
disease, how it should be treated, and the populations it affects.
As policymakers consider whether and how to reauthorize this impor-
tant program, they must anticipate the future: they have to envision
who will need services funded by Ryan White over the next five years,
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consider the type of care they will need, and determine how much money
to allocate for it. They will need to struggle with the paradox of provid-
ing equitable access to services and life-extending prescription drugs
through a program designed to fill the access gaps unique to each state’s
health care safety net. They will contemplate the next phase of Ryan White
against the backdrop of significant federal deficits, Medicaid reform de-
bates, an estimated 45 million uninsured, and continually increasing health
care costs. A significant policymaking challenge lies ahead.
This background paper is divided into four sections.
■ The first section discusses the disease’s pathology and its treatment,
provides information on the data used to understand the magnitude
of the epidemic, and profiles the populations most affected by HIV/
AIDS in the United States. This background section is essential for
understanding the key resource allocation and funding prioritization
debates discussed in the last section of the paper.
■ Section two examines how the federal government addresses HIV/
AIDS both domestically and globally. It highlights treatment, research,
and prevention efforts by discussing the agencies involved and the
funds allocated. Special emphasis is placed on providing a context for
Ryan White as the payer of last resort amidst other federal programs
that fund HIV/AIDS treatment services.
■ The third section lays out the statutory structure of the CARE Act,
including a discussion of the mechanisms used for distributing
funds, the recipients of those funds, and their intended purpose.
■ The final section examines policy issues for consideration in the next
reauthorization, should one occur.
BACKGROUND
The HIV/AIDS epidemic in the United States is well into its third decade.
The first cases of Acquired Immunodeficiency Syndrome (AIDS) were re-
ported in the United States in 1981; since then 524,060 people with AIDS
have died.1 In 1984, scientists identified HIV as the cause of AIDS.
HIV/AIDS Disease and Treatment
Most commonly, HIV is contracted through sexual contact with an in-
fected person, sharing needles or syringes with an infected person, or,
less commonly, by receiving infected blood products. Babies born to HIV-
positive mothers may become infected before or during birth or through
breastfeeding. There is currently no vaccine to prevent transmission of
HIV and no cure.
HIV commandeers the body’s immune system by destroying white blood
cells called CD4+ T lymphocytes (CD4+ T cells) that are a critical part of
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the immune system. A healthy, uninfected person
usually has between 800 and 1200 CD4+ T cells per
cubic milliliter of blood (mm3). A person’s condition
is said to have progressed to AIDS when their CD4+ T
cell count has fallen below 200 cells per mm3 of blood,
severely hindering the body’s ability to ward off in-
fection. Specific “opportunistic infections” thrive
in the immune-compromised body; for instance, yeast
can infect the mouth, which is known as oral thrush,
and a certain type of cancer called Kaposi’s sarcoma
causes lesions on the skin and other parts of the body.
Conditions such as these are extremely rare—if found
at all—in people with uncompromised immune
systems, and thus signal the advanced stage of HIV
infection, or AIDS. HIV/AIDS refers to all persons
known to be infected with HIV even if they have not
been diagnosed with AIDS.
When AIDS was first diagnosed in the United States in the 1980s, patients
typically lived less than a few years and little more than end-of-life or pal-
liative care was available. Since then, researchers have created a number of
drugs that can suppress HIV in the body and extend lifespan significantly.
The category of medications that fight HIV by preventing replication is
called antiretrovirals. The Food and Drug Administration (FDA) has ap-
proved more than 20 antiretroviral medications or combinations of
antiretrovirals for HIV treatment that fall into four classes, corresponding
to the way the body can fight the virus. Because HIV can become resistant
to any one drug, people living with HIV/AIDS typically take a combina-
tion of drugs from different classes. This combination treatment is known
as highly active antiretroviral therapy (HAART). The Public Health Ser-
vice (PHS) publishes HIV treatment guidelines, which are widely accepted
as the standard of care for HIV/AIDS.
Access and adherence to comprehensive antiretroviral therapy is the corner-
stone of HIV care. High levels of treatment adherence are critical to suppress
the virus in the blood and also to prevent development of drug-resistant
strains of the virus. Patients often find it challenging to adhere to the HAART
regimen because it is complex with multiple dosing and dietary restrictions,
and the medications often have side effects that can make patients feel worse.
In addition, the regimen is extraordinarily expensive: a year’s supply of
antiretrovirals can cost $12,000 or more per person, and when the costs of
doctor’s visits, laboratory tests, and drugs to prevent or treat opportunistic
infections are added in, the total can grow to $18,000 to $20,000.2
With the introduction of HAART in 1996, the standard of care for HIV/
AIDS shifted from acute, hospital-based, and palliative care to chronic
disease management through primary medical care and related sup-
portive services. The percentage of deaths attributable to AIDS peaked
in 1995 and declined by 70 percent between 1995 and 2002 as a result of
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HAART. There were an estimated 18,017 deaths of persons with AIDS in
the United States in 2003 for a total of 524,060 since the beginning of the
epidemic. Antiretrovirals have also led to dramatic successes in curbing
perinatal (mother to child) transmission of HIV/AIDS. Perinatal transmis-
sion has declined from a 25 percent risk of transmission to less than 2 per-
cent when antiretrovirals are administered during pregnancy and certain
obstetrical interventions are followed.3
Counting Cases
Testing individuals for HIV and reporting positive diagnoses to public
health authorities is critical to determining the magnitude of the HIV/
AIDS epidemic in the United States, informing prevention activities, esti-
mating treatment needs, and initiating treatment. Since the beginning of
the epidemic, standard testing for HIV involved drawing blood to test
for the presence of antibodies specific to HIV. Antibodies occur in the
bloodstream when the body is fighting an infection, and these antibodies
are uniquely configured to match invading microorganisms. There are
limitations to testing the blood for HIV, namely that it does not detect the
infection in its earliest stage, when people have the highest viral load and
are most infectious. It may take three months or longer until detectable
antibodies develop, and test results typically take several days to two
weeks to process, which requires those tested to follow up to learn their
results. In 2000, 31 percent of people who tested positive for HIV through
the Centers for Disease Control and Prevention (CDC)–funded tests did
not return for their results.4
Continual improvements in testing techniques for HIV have addressed
some of the concerns with existing tests, but challenges remain. In 2002,
the FDA began approving “rapid” HIV tests that use blood from a finger
prick, instead of blood drawn from a vein. In 2004, the FDA approved the
first rapid test using oral fluid instead of blood.5 These tests can produce
initial results in as little as 20 minutes, eliminating the problem of indi-
viduals having to return days later to learn their results. The CDC and
the Substance Abuse and Mental Health Services Administration
(SAMHSA) have both been purchasing and deploying these rapid HIV
tests. However, rapid testing, like traditional testing, does not detect the
virus in the earliest stages of infection.
Testing for the virus itself, by testing for its genetic information called RNA
(as opposed to testing for the antibodies that recognize the virus), is pos-
sible but is more expensive than testing for antibodies and is not widely
used for diagnostic purposes. This type of test is typically used to monitor
viral loads and guide treatment of those who have already tested HIV-
positive. Only one state, North Carolina, uses it for all of its publicly funded
testing.6 Commercial viral load tests can cost $200 to $300 each, compared
with $5 for the antibody test. As a double-check measure, North Carolina
takes the blood of every person who tests negative using the antibody
test at their sexually transmitted disease (STD) clinics and pools them
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into batches of 90 to test the viral load. Any batch that tests positive is
subdivided and tested until the positive sample is found. By using this
dual testing process, North Carolina has identified an additional 6 per-
cent of HIV cases in its clinics. The state has reduced the cost of combined
HIV antibody and viral load testing from $90 to $3.63. San Francisco has
been doing the same thing in its STD clinics since 2003 and estimates its
costs at about $30 per person.7
The testing and reporting of positive test results to public health authori-
ties can be done either confidentially or anonymously. With confidential
testing and reporting, the person’s name is recorded with the test results;
with anonymous testing, no name is recorded (see text box). All 50 states
have had mandatory confidential name-based AIDS case reporting since
Name-based HIV case reporting has been more con-
tentious than name-based AIDS reporting. The
controversy revolves around fear that government
entities will not safeguard the information appro-
priately and that the risks of invasion of privacy and
discrimination outweigh the public benefit from the
appropriate use of the information. There was less
resistance to name-based AIDS case reporting from
the beginning of the epidemic because the length of
time between AIDS diagnosis and death was so short
and the need for medical services was so great that
these needs outweighed privacy concerns.
Although all states now report HIV cases, they do it
in three different ways, which creates problems for
the comparison and aggregation of data at the na-
tional level. Currently, 38 states report HIV cases by
name; 7 states report HIV cases by code, and 5 states
initially report by name but then convert the infor-
mation to code after follow-up and data collection
are complete. The District of Columbia and the city
of Philadelphia report HIV cases by code, and Puerto
Rico reports by name. Georgia is the most recent state
to implement a name-based HIV reporting system;
it began providing data to the CDC in December
2003. It is important to note that the CDC never re-
ceives actual names with AIDS or HIV reports.
Name-based reporting refers to the way the case is
reported from the laboratory to the local authorities
and then the local to the state authorities. All name-
based AIDS and HIV case reports are converted to
an alphanumeric code based on the person’s last
name, gender, date of birth, and social security
number before being submitted to the CDC. The
CDC checks these alphanumeric codes for appar-
ent duplication and goes back to any state(s) in-
volved to work out any suspected duplications.
Because all states do not collect name-based HIV re-
ports, they cannot provide an alphanumeric code to
the CDC that would allow the agency to eliminate
duplication. Therefore, the CDC’s national HIV esti-
mates include data from only the 33 areas (32 states
and the U.S. Virgin Islands) that they consider to have
mature, name-based surveillance systems. HIV sur-
veillance system maturity is important to ensure data
accuracy. Many states with recent HIV reporting sys-
tems have significantly fewer reports because of the
time lag in entering cases found before the new sys-
tem was put in place.
The CDC’s HIV estimates exclude data from four
of the ten states with the highest number of cumu-
lative AIDS cases (California, Illinois, Maryland,
and Massachusetts) because those states report their
HIV cases by codes that are not linked to names.
The 33 areas from which CDC creates its HIV esti-
mates represent 43 percent of total national reported
AIDS cases.*
* Kaiser Family Foundation (KFF), “The HIV/AIDS Epidemic in the
United States,” fact sheet, updated December 2004; available at
www.kff.org/hivaids/3029-04.cfm.
What’s in a Name? HIV Case Reporting
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early in the epidemic and, as a result, information on national AIDS cases
and new cases each year is relatively complete and available. Authority
for mandating disease reporting lies with the state, but all states volun-
tarily report AIDS data to the CDC.
Ryan White CARE Act funds are distributed on the basis of estimated
living AIDS cases (ELCs). The CDC determines ELCs by weighting an-
nual survival rates for the most recent 10 years of reported AIDS cases in
a state or metropolitan area.
A Profile of the Epidemic
Testing and case reporting allowed the CDC to better understand how
HIV/AIDS is affecting the U.S. population. Because HAART has allowed
people with HIV/AIDS to live longer lives, HIV/AIDS prevalence con-
tinues to grow. The CDC estimates that between 1,039,000 and 1,185,000
people are living with HIV/AIDS in the United States (this is known as
HIV/AIDS prevalence) and that a quarter of this infected population is
unaware of its status.8 It is estimated that this undiagnosed population is
responsible for about 66 percent of new infections each year.9
Increasing numbers of people living with HIV/AIDS create greater risk for
new infections in the absence of aggressive prevention and place escalat-
ing demands on the health care system (Figure 1). The CDC estimates that
40,000 new infections occur each year; this is known as HIV incidence.
FIGURE 1
Estimated HIV Infection Incidence and Prevalence in the United States, 1977 to 2003
Note: The CDC changed the way it measures HIV incidence in 1994. For more information, contact the HIV Incidence and Case Surveillance Branch
within the Divisions of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention.
Source: Adapted from figure 1 of Robert S. Janssen, CDC, “Domestic HIV/AIDS Surveillance: Current Trends and Status of HIV Reporting,” testimony
before  Committee on Homeland Security and Governmental Affairs, Subcommittee on Federal Financial Management Government Information, and Inter-
national Security, U.S. Senate, June 23, 2005; available at www.hhs.gov/asl/testify/t050623a.html.
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About 18,000 people die from AIDS-related condi-
tions each year, and an additional 22,000 people seek
HIV/AIDS services each year.10
Racial and ethnic minorities, especially African Ameri-
cans, have been disproportionately affected by HIV/
AIDS. In 2003, African Americans comprised only 13
percent of the total U.S. population but represented
49 percent of the estimated 43,171 new AIDS cases.
Women are also increasingly affected by HIV/AIDS.
New AIDS diagnoses among women have increased
from 8 percent in 1985 to 27 percent in 2003.
While men who have sex with men are still the larg-
est transmission group for HIV/AIDS, heterosexual
transmission has increased significantly. Between
1985 and 2003, heterosexual transmission increased
from 3 to 31 percent of newly diagnosed AIDS cases.
The percentage for men who have sex with men
dropped from 65 to 42 percent but has been slowly
increasing in the last few years. Cases attributable to
injection drug use remained relatively steady rising
from 19 to 22 percent in 2003 (Figure 2). 11
In terms of geographic distribution of the epidemic,
the southern states were home to the greatest num-
ber of people living with AIDS, the largest number of
newly diagnosed AIDS cases, and the highest num-
ber of AIDS deaths in 2003. At 21.1 per 100,000 people,
northeastern states had the highest AIDS case rate fol-
lowed by southern states with 18.8, western states with
10.0, and mid-western states with 6.9 per 100,000
people. In 2003, the top five states by cumulative AIDS
cases were New York, California, Florida, Texas, and
New Jersey. The top five states or areas by case rate
were the District of Columbia, New York, the Virgin
Islands, Maryland, and Puerto Rico.12
It is difficult to determine insurance coverage among
people with HIV/AIDS because many are not in the
care system and a significant portion do not know their
HIV status. The CDC estimates that just 41 to 58 per-
cent of people with HIV/AIDS are actually receiving
regular care. The HIV Cost and Services Utilization
Study (HCSUS) is the only nationally representative
study of people living with HIV/AIDS who are receiv-
ing care.13 The study, conducted between 1996 and 1998,
found that 29 percent of people living with HIV/AIDS
in care were covered by Medicaid alone, 6 percent were
FIGURE 2
Percentage of New AIDS Cases in 2003,
by Race/Ethnicity, Gender, and
Transmission Category
Source: CDC, HIV/AIDS Surveillance Report: Cases of HIV Infection
and AIDS in the United States, 2003, 15, table 7; available at www.cdc.gov/
hiv/stats/2003SurveillanceReport.htm.
Race/Ethnicity
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covered by Medicare only, 31 percent had pri-
vate insurance, and 20 percent were unin-
sured. About 12 to 13 percent of people with
HIV/AIDS in care are dually eligible for
Medicaid and Medicare. By comparison, for
American adults overall, 8 percent were cov-
ered by Medicaid, 2 percent by Medicare, 70
percent by private insurance, and 20 percent
were uninsured.14
People living with HIV/AIDS increasingly
have complex needs that further complicate
treatment and impede adherence to treat-
ment. These special needs include
comorbidities, additional diseases or condi-
tions, such as mental illness, substance abuse
disorders, hepatitis, sexually transmitted
diseases, or tuberculosis, as well as vulner-
able social conditions such as homelessness
and incarceration. These medical comorbidities and social vulnerabili-
ties often coexist, as well. It is estimated that about 50 percent of people
with HIV who are in care have some form of comorbid mental illness.15
About one-quarter of all HIV-infected individuals are estimated to have
comorbid hepatitis C infection.16 One analysis found that between 20
and 26 percent of all people living with HIV/AIDS passed through a
correctional facility in 1997.17
FEDERAL HIV/AIDS EFFORTS
The changes in HIV/AIDS treatment from a palliative care to a chronic
care model and the shifting demographics with respect to race and
ethnicity, mode of transmission, gender, and geography make crafting
a health care system and public financing response to the disease chal-
lenging. Whether for humanitarian or public health reasons, there are
compelling arguments for addressing the epidemic domestically and glo-
bally. The federal government’s efforts to address the HIV/AIDS epidemic
focus on providing treatment and support services, conducting research,
and trying to prevent new infections (Figure 3, above). The challenge lies
in developing and funding these separate activities but also in integrat-
ing the experiences from each to inform the other both domestically and
globally. (See text box, “The Global HIV/AIDS Epidemic,” next page.)
There are a number of organizations involved in crafting federal domes-
tic HIV/AIDS policy. In the Executive branch, efforts are spearheaded
by the White House Domestic Policy Council and Office of National
AIDS Policy (ONAP). The President’s Advisory Council on HIV/AIDS
(PACHA) also makes policy recommendations to the White House.
Continued on page 12 ➤
FIGURE 3
Federal Funding of HIV/AIDS
for FY 2005
Source: Adapted from Kaiser Family Foundation “U.S. Federal Funding for HIV/AIDS:
The FY 2006 Budget Request,” fact sheet, February 2005; available at www.kff.org/hivaids/
upload/Fact-Sheet-U-S-Federal-Funding-for-HIV-AIDS-The-FY-2006-Budget-Request.pdf.
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In the over two decades since the beginning of the
HIV/AIDS epidemic, over 60 million people have
become infected and over 20 million have died of
AIDS-related causes. In 2004 there were 39.4 mil-
lion people estimated to be living with HIV/AIDS
worldwide. HIV is the leading cause of death glo-
bally for people ages 15 to 59. Sub-Saharan Africa,
a region that comprises 10 percent of the world’s
population, bears the brunt of the global epidemic
with 64 percent of the entire global infected popu-
lation. There is concern that a new wave of the epi-
demic is taking place in Asia and Eastern Europe.
Unlike the United States, where women constitute
about 25 percent of HIV/AIDS cases, women rep-
resent 45 percent of people living with HIV/AIDS
globally and 57 percent of the infected population
in sub-Saharan Africa. The United Nations esti-
mates that nine out of ten people who need treat-
ment for HIV/AIDS are not receiving it.*
The U.S. government plays a key role in funding
prevention, treatment, and research efforts to re-
spond to the global HIV/AIDS epidemic. The
United States donates to the Global Fund to Fight
AIDS, Tuberculosis, and Malaria, an independent,
international public-private partnership created in
2001 to fund prevention, treatment, and research
efforts. In addition, in 2003, Congress and Presi-
dent Bush created the President’s Emergency Plan
for AIDS Relief (PEPFAR) a five-year, $15 billion
effort. PEPFAR is targeting funds to 15 focus coun-
tries in Africa, Asia, and the Caribbean that com-
prise about half of all infections globally. Its goals
are to support treatment for 2 million people, pre-
vent 7 million new infections, and support care
for those infected and affected by the epidemic by
2008. The Office of the U.S. Global AIDS Coordi-
nator at the U.S. Department of State coordinates
the global AIDS response of the United States. U.S.
funding to combat the global epidemic totaled $2.6
billion in FY 2005, including $347 million for the
Global Fund, $1.4 billion for the Global AIDS
Coordinator’s Office, and the remainder for efforts
The Global HIV/AIDS Epidemic
funded through the U.S. Agency for International
Development (USAID), Department of Health and
Human Services (DHHS), Department of Defense,
and Department of Labor.**
There have been some controversies surrounding
PEPFAR policies. The U.S. government requires that
any antiretroviral purchased using PEPFAR funds
be FDA approved. The only FDA-approved
antiretrovirals sold in the United States are brand
name, not generic, because of drug manufacturer pat-
ents and exclusivity agreements. Many HIV/AIDS
advocates have criticized the Bush administration
for requiring FDA approval for PEPFAR-purchased
drugs. They argue that the requirement increases
the profits of U.S. patent–holding pharmaceutical
companies at the expense of people with HIV/AIDS
in developing countries, more of whom could be
treated if less expensive, generic drugs could be pur-
chased by PEPFAR. In response, in May 2004,
DHHS announced an expedited FDA review pro-
cess for single-ingredient, fixed-dose combination,
and co-packaged generic antiretrovirals as well as
brand-name fixed-dose combination and co-pack-
aged antiretovirals.*** The agency has approved
nine medications since it implemented the expe-
dited process. The Bush administration has also
been criticized for overemphasizing abstinence as
a prevention method, compared with other strate-
gies like promoting condom use.
* UNAIDS, 2004 Report on the Global AIDS Epidemic, July
2004; available at www.unaids.org/bangkok2004/GAR2004_html/
GAR2004_00_en.htm; and UNAIDS, AIDS Epidemic Update,
December 2004; available at www.unaids.org/wad2004/
EPIupdate2004_html_en/epi04_00_en.htm
** KFF, “U.S. Federal Funding for HIV/AIDS: The FY 2006 Budget
Request,” HIV/AIDS Policy fact sheet, February 2005; available at
www.kff.org/hivaids/upload/Fact-Sheet-U-S-Federal-Funding-for-
HIV-AIDS-The-FY-2006-Budget-Request.pdf.
*** Fixed-dose combination drugs create one pill out of two or three
individual drugs, whereas co-packaging means putting two or three
pills into a single package for distribution. FDA, “FDA Review of
HIV Drugs,” fact sheet, May 16, 2004; available at www.hhs.gov/
news/press/2004pres/20040516a.html.
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Medicaid pays for services for
about 55 percent of people living
with AIDS.
➤  Continued from page 10
The bulk of federal effort and funding for health-related efforts for people
living with HIV/AIDS is housed within the Department of Health and
Human Services (DHHS). Within DHHS, the Office of HIV/AIDS Policy
(OHAP) serves as the coordinator for the efforts in treatment (the Centers
for Medicare and Medicaid Services, the Health Resources and Services
Administration, and SAMHSA), in research (the National Institutes of
Health), and in prevention (the CDC). The Departments of Veterans Affairs
and Housing and Urban Development and the Social Security Administra-
tion also fund key programs that provide health care, housing, and income
support to people living with HIV/AIDS.
Treatment Funding Streams
At a public health level, treating people with HIV/AIDS is critical for
reducing viral load, and therefore infectiousness and transmission, and
for providing the opportunity to reinforce prevention. In terms of federal
dollars for treatment, the Medicaid program is the largest funder of health
care services for people living with HIV/AIDS, with Medicare second,
and Ryan White third. Both Medicaid and Medicare are en-
titlement programs, meaning that the federal government
must pay for services as long as eligible individuals seek
them; federal funding cannot be capped nor can waiting
lists be created. Ryan White, on the other hand, is a discre-
tionary grant program, meaning that it is appropriated a finite amount of
funds by Congress each year which may or may not be sufficient to meet
the demand for services by those who rely on it. In fiscal year 2005, Med-
icaid spent $5.7 billion in federal matching funds to finance HIV/AIDS
treatment, Medicare financed $2.9 billion for treatment of HIV/AIDS, and
Ryan White was appropriated $ 2.1 billion.
Medicaid — Medicaid is a state/federal program to finance health care
coverage for certain low-income children, families, and pregnant women,
as well as the elderly and disabled. It covers approximately 55 percent of
people living with AIDS and up to 90 percent of all children with AIDS.18
The vast majority of people living with HIV/AIDS who qualify for Med-
icaid do so because they are disabled and receive cash assistance through
the Supplemental Security Income (SSI) program. 19 To meet the SSI medi-
cal definition of disability, an individual’s HIV infection must have pro-
gressed significantly, meaning that he or she qualifies for Medicaid at a
time when the disease is more advanced and his or her care needs are
highest and potentially most expensive. In addition to meeting the SSI
definition of disability, individuals must also be low-income and have
limited resources to receive SSI cash benefits.20
Within the federal Medicaid framework, states have significant flexibility
to define eligibility categories, the scope and duration of benefits, and pro-
vider payment rates. “Medically needy” is an optional eligibility category
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under which the state can deduct the cost of an individual’s medical
care from their annual income so people can “spend down” to become
Medicaid-eligible. According the Henry J. Kaiser Family Foundation, 33
states use the medically needy category for the disabled, and many people
living with HIV/AIDS qualify for benefits this way.
Benefits like inpatient and outpatient hospital services, physician services,
and laboratory and x-ray services are mandatory in the Medicaid program,
whereas prescription drug coverage, dental services, targeted case man-
agement, and hospice care are optional. All states have chosen to provide
prescription drug coverage, and they cover all FDA-approved HAART
drugs, but the amount and scope of coverage is at the
state’s discretion. Some states are trying to contain
Medicaid pharmaceutical costs by limiting the num-
ber of brand-name prescriptions beneficiaries may fill
each month and by encouraging the use of generic
drugs. Because HIV/AIDS patients typically take a
combination of at least three medications and no generic antiretrovirals are
currently available in the United States, these pharmacy benefit policies
negatively affect their access to care. Many more states have placed limits
on the overall number of prescriptions available to a beneficiary per month.
These policies place hardships on beneficiaries and increase the fiscal bur-
den on state AIDS Drug Assistance Programs (ADAP) (discussed more later
in the paper), since most persons living with HIV/AIDS require a range of
medications to attack the virus, manage side effects from treatment, and
treat common comorbidities.
Medicare — Medicare is the second largest federal payer of HIV/AIDS
care in the United States. Approximately 85,000 people living with HIV/
AIDS, or about 19 percent of people living with HIV/AIDS who are in
care, are Medicare-eligible. About 55,000 of those beneficiaries are dually
eligible for both Medicaid and Medicare.21 Currently, the vast majority of
Medicare beneficiaries with HIV/AIDS qualify because of disability sta-
tus, not because they are age 65 or older (about 3 percent of people living
with AIDS are age 65 or older).22 They have met the SSA disability defini-
tion and have earned enough work credits to receive Social Security Dis-
ability Insurance (SSDI) payments. Under the SSDI program, there is a
5-month waiting period for income benefits after becoming disabled and
an additional 24-month waiting period before Medicare coverage begins.23
As people with HIV/AIDS continue to live longer because of HAART,
more and more will become eligible for Medicare benefits as they age.
Although Medicare has not historically covered outpatient prescription
drugs, most Medicare beneficiaries with HIV/AIDS are dually eligible
for Medicaid and Medicare and therefore have had access to prescription
drug coverage at minimal cost. Those who are not dually eligible, how-
ever, have had to find other ways to pay for HAART, like turning to state
ADAPs. On January 1, 2006 a new Medicare prescription drug benefit
Most people with HIV/AIDS who are
covered by Medicaid or Medicare
qualify for those programs because
they are considered disabled.
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goes into effect. On that day, those who are dually eligible will begin
receiving their prescription drugs from Medicare instead of Medicaid.
CMS is requiring all participating prescription drug plans to offer all
drugs used to treat HIV/AIDS in their formularies.24 This requirement
is meant to ensure that Medicare beneficiaries with HIV/AIDS will have
access to the drugs they need; it is also meant to prevent drug plans
from discouraging people with HIV/AIDS from joining their plans by
not offering all HIV/AIDS drugs in their formularies. Despite this pro-
tection, the future impact of this program on Medicare beneficiaries with
HIV/AIDS is unclear and will be important to monitor.
The Ryan White CARE Act — The CARE Act was named for Ryan White,
a teenager from Indiana who was born a hemophiliac and contracted
HIV from infected blood that he received in a transfusion. At age 10, he
was barred from attending public school by parents and administrators
who feared he might infect others. He spent his life educating the pub-
lic about the disease until his death in 1990 at age 18. The Ryan White
Comprehensive AIDS Resources Emergency (CARE) Act, named in his
honor, was first authorized in 1990 and has since been reauthorized in
1996 and 2000 with a current expiration of September 30, 2005. The au-
thorizing committees of jurisdiction are the Senate Committee on Health,
Education, Labor and Pensions (HELP) and the House Committee on
Energy and Commerce. Unlike Medicaid and Medicare, the CARE Act
is not a health insurance program, but instead is a source of grant fund-
ing that serves as the payer of last resort for services provided to people
with HIV/AIDS who are either uninsured or underinsured. Total FY
2005 federal funding for the CARE Act was $2.1 billion.
The program provides medical and support services to low-income, un-
insured, vulnerable populations disproportionately affected by the epi-
demic. It serves approximately 533,000 individuals and families living
with HIV/AIDS each year. In 2002, 46 percent of Ryan White clients were
African American, 20 percent were Hispanic, and about one-third were
women. At least one of every two clients lived below the federal poverty
level, about 25 percent were uninsured, less than 10 percent had any pri-
vate health insurance, and about 28 percent were enrolled in Medicaid.25
Research Programs
Federal research funding on HIV/AIDS in FY 2005 totaled $2.9 billion,
17 percent of total federal domestic spending on HIV/AIDS that year.
The NIH Office of AIDS Research is responsible for coordinating all bud-
getary, research, policy, and legislative aspects of the agency’s AIDS
research program. A number of the agency’s institutes participate in
HIV/AIDS research, and their efforts contribute to the $2.9 billion total.
The largest amount, $1.5 billion, is from the National Institute of Al-
lergy and Infectious Diseases.
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NIH’s research focuses on understanding the basic science of the disease
(its transmission, how it progresses, and its genetic structure); investigat-
ing possible ways to prevent and reduce HIV transmission, including
microbicides, vaccines, and behavioral interventions; developing better
therapies for those already infected; refining approaches to address the
epidemic in developing countries; and studying the behavioral and bio-
medical aspects of the disproportionate impact of the disease on racial
and minority populations in this country. In FY 2005, 37 percent of NIH’s
research dollars was targeted to the basic science of the disease, 25 per-
cent to the development of therapeutics, 17 percent to the search for a
vaccine, 14 percent to behavioral interventions, and the remaining 7 per-
cent to training, infrastructure, and information dissemination.26
Thus far, NIH funding has supported 70 clinical trials of nearly 40 vac-
cine candidates.27 An article in the July 2005 issue of the journal Science
discussed the feasibility of developing an effective HIV vaccine. Broadly,
vaccine approaches include stimulating the production of antibodies as
well as cellular immunity. Some researchers argue that a vaccine will
never stop HIV, whereas others believe a vaccine is achievable. Propo-
nents of the view that vaccines are feasible point to monkey experiments
which demonstrated that vaccines could protect animals from a relative
of HIV. In addition, there are studies of individuals who have an appar-
ent innate resistance to the virus, meaning they have never become in-
fected despite multiple exposures to HIV, to see if that resistance can be
identified and mimicked. While NIH’s $507 million dedicated to the
vaccine effort in FY 2005 supports numerous studies and clinical trials,
author Jon Cohen concluded that discovery of an effective AIDS vac-
cine “remains a distant dream.”28
The focus in the area of therapeutic research is multifaceted and includes
creating new and better treatments with fewer side effects and toxici-
ties, limited development of drug resistance, reduced cost, and improved
potential for patient compliance. Researchers are studying optimal
therapy strategies including when to start, change, sequence, or inter-
rupt therapies. Developing treatments for coinfections like hepatitis B
and C and tuberculosis is another priority, as is continuing to find safe,
effective, convenient strategies for interrupting perinatal transmission.
Efforts are also under way to develop treatments that can be implemented
in international settings.29
Prevention
Prevention of new HIV infections is critical to reduce disease burden and
contain treatment costs. Thirty-eight percent of all HIV infections diagnosed
in 2002 progressed to AIDS within 12 months, which shows there contin-
ues to be a significant need to get people tested and quickly into treatment
before their disease progresses.30 HIV prevention strategies have included
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Federal HIV/AIDS funding in the
United States is primarily focused on
providing treatment, as opposed to
research or prevention.
population-based campaigns promoting sexual abstinence or condom use.
Other strategies focus on identifying individuals who are already infected
to prevent further transmission. Needle exchange programs to prevent
transmission among injection drug users are another type of HIV preven-
tion that the U.S. government does not support; in fact, it is illegal to use
federal dollars to support such programs.
The CDC leads the government’s HIV/AIDS prevention efforts. The
agency was appropriated $732 million in FY 2005 to conduct these ef-
forts. This federal investment in HIV/AIDS prevention amounts to 4
percent of total federal HIV/AIDS funding. The agency’s National Cen-
ter for HIV, STD, and TB Prevention within the newly created Coordi-
nating Center for Infectious Diseases organizes agency-wide efforts. The
CDC distributes most of its funding to state and local health depart-
ments to conduct disease surveillance; fund HIV testing, counseling,
and referral; and promote public understanding and awareness.
In April 2003, the CDC launched a new initiative “Ad-
vancing HIV Prevention (AHP): New Strategies for a
Changing Epidemic” that consists of targeting efforts
around four strategies for preventing HIV infections:
(a) making HIV testing a routine part of medical care;
(b) implementing new models for diagnosing HIV
outside the medical setting; (c) working with HIV-positive persons and
their partners to prevent new infections; and (d) further reducing peri-
natal transmission of HIV.31 The new initiative is an effort to help the
CDC meet its current prevention goals. Two of the goals are to halve
the estimated 40,000 new infections each year and to increase the pro-
portion of HIV infected people who know their status from 70 to 95
percent by 2005.
Some researchers argue that these four interventions will likely achieve
only about one-third of the CDC’s goal of preventing 20,000 new infec-
tions each year. Such critics maintain that the CDC should utilize cost-
effectiveness modeling to determine the most cost-effective interventions
and to target limited prevention dollars accordingly. For example, strate-
gies that target high prevalence groups like men who have sex with men
or places where high prevalence groups seek care, like STD clinics, are
significantly more cost-effective per infection prevented than standard
counseling and testing.32
The aforementioned distribution of federal funding illustrates that the
domestic HIV/AIDS policy in the United States is primarily focused on
providing treatment services. Although research and prevention are clearly
important, the remainder of this paper will focus on funding for HIV/
AIDS treatment services, particularly Ryan White, the government’s larg-
est discretionary funder of such services.
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AN ACT, IN FOUR TITLES AND A PART
As the HIV/AIDS epidemic unfolded in the 1980s, Congress began to
hear from public health officials, urban public hospitals, and those in-
fected about the personal and financial burdens of the disease. Con-
gress responded in the late 1980s by funding demonstration programs
in those urban areas most affected by the epidemic. The programs fo-
cused on developing community-based HIV/AIDS systems of care;
purchasing AZT, the first FDA-approved antiretroviral drug; and ad-
dressing the needs of HIV-infected pregnant women and children.33 The
demonstrations were funded through annual appropriations bills and
provided the framework for the future Ryan White CARE Act. The CARE
Act was signed into law on August 18, 1990 and became Title XXVI of
the Public Health Service Act.
The Act authorized a discretionary grant program
“to provide emergency assistance to localities that
are disproportionately affected by the Human Im-
munodeficiency Virus epidemic and to make fi-
nancial assistance available to States and other
public or private nonprofit entities to provide for
the development, organization, coordination and
operation of more effective and cost efficient sys-
tems for the delivery of essential services to indi-
viduals and families with HIV disease.”34 The
Health Resources and Services Administration
(HRSA) within DHHS administers the Act
through the HIV/AIDS Bureau (HAB).
The Ryan White CARE Act is organized into four
titles. Each title directs funds to a different type of
recipient in an effort to ensure a community-driven
treatment response but also to maximize state-level
involvement where appropriate. For example, Title
I is geared to cities, Title II to states, and Titles III
and IV to community-based providers. The fund-
ing distribution mechanisms also vary across the
titles. Title I uses both formula and competitive grants, Title II formula
grants, and Titles III and IV competitive grants. Eighty-five percent of Ryan
White funds are distributed through Titles I and II of the Act (Figure 4).
Title I (Part A) of the CARE Act
The first title of the Act provides funds to metropolitan areas with sig-
nificant need for services, specifically eligible metropolitan areas (EMAs)
that have a population of at least 500,000 and more than 2,000 ELCs
within the past five years. Half of the funds are distributed through
formula grants and the other half through competitive supplemental
FIGURE 4
Ryan White CARE Act Funding by Title, FY 2005
Note: Percentages do not add up to 100, due to rounding.
Source: HRSA, “Appropriations History: FY 1991 to FY 2005,” table, January
4, 2005, available at ftp://ftp.hrsa.gov/hab/fundinghis04.xls; and HRSA, Fiscal
Year 2006: Justification of Estimates for Appropriations Committees, avail-
able at www.hhs.gov/budget/06budget/documents/HRSABudget06.pdf.
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grants on the basis of severity of need criteria. The FY 2005 appropria-
tion for Title I was $618 million.
An EMA’s formula grant is based on its proportion of ELCs compared
to all ELCs across all EMAs. In FY 2005, 51 EMAs were funded in 21
states, Puerto Rico, and the District of Columbia (see text box, below).
Supplemental grants are awarded through a narrative grant applica-
tion process that is designed to illustrate an EMA’s severe need for
supplemental financial assistance, its local resources committed to ad-
dress the disease, its ability to utilize funds cost-effectively, and its abil-
ity to allocate resources according to local disease demographics. By
statute, the severe need criteria accounts for one-third of the weight of
all application review factors.
Title I grant funds may be used for “outpatient and ambulatory health ser-
vices, including substance abuse treatment, mental health treatment, and
comprehensive treatment services,…outpatient and ambulatory support
services (including case management), to the extent that such services
facilitate, enhance, support, or sustain the delivery, continuity, or benefits
of health services for individuals and families with HIV disease.”35 They
may also be used for inpatient case management services and outreach
activities focused on identifying people who know their HIV status and
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are not treating their disease. The statute mandates that funds be allo-
cated to services for infants, children, and women in the proportion that
they are represented in the HIV/AIDS population of the EMA.
Grants are awarded to the chief elected official of the city or county
agency that provides health care services to the largest number of people
living with AIDS, generally the local health department. That official
appoints a local planning council, of which at least 33 percent of the
members must be either people living with HIV/AIDS or the parent or
a caregiver of a child with HIV/AIDS. There must also be representa-
tion from health care providers, mental health and substance abuse pro-
viders, and the prison system, among others. The local planning council’s
key duties are (a) to determine the size and demographics of the
HIV-positive population; (b) to determine the needs of the population,
with special attention to those who know their positive status but are
not in care and those disproportionately affected and historically
underserved populations; (c) to establish funding priorities; and (d) to
develop a comprehensive plan for the delivery of health and support
services to the population.
The 1996 reauthorization changed the basis of the funding formula for
Titles I and II from cumulative AIDS cases (living or deceased) since 1981
to the number of ELCs. Had this change been implemented without modi-
fication, it would have created significant shifts in funding away from
areas most affected by the epidemic in the early years. As a result, Con-
gress added a hold harmless provision to Title I that would be triggered
if any changes in ELCs for an EMA would result in decreased funding.
Once the provision is triggered, the grant will decline each year to 98
percent, 95 percent, 92 percent, and 89 percent of the base year grant. In
all subsequent years, the EMA will receive 85 percent of its base year
grant. Another provision in the 1996 reauthorization “grandfathered”
existing EMAs by establishing that if an EMA was eligible in FY 1996 for
Title I funding, it will always receive funding regardless of whether its
ELCs or population size drops below statutory levels.
The 2000 reauthorization included a study by the Institute of Medicine
(IOM) to examine, among other things, the overall financial impact of
distributing Ryan White funding on the basis of HIV infection instead of
AIDS diagnosis. Following the recommendations of that report, the reau-
thorization required the Secretary of DHHS to determine whether state
HIV data was accurate and reliable enough to be used in place of AIDS
data for Ryan White planning and funding allocation. To date, the Secre-
tary has determined that Ryan White funding allocations should continue
to be made based on AIDS case data. Regardless of the IOM’s report and
Secretary’s decision, the statute currently requires that HIV data be used
as the basis for allocating funds starting in FY 2007.
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Title II (Part B) of the CARE Act
Title II funds three types of formula grants: base grants, AIDS Drug As-
sistance Program (ADAP) grants, and emerging communities grants. In
FY 2005, Congress appropriated $1.14 billion for Title II.
Base Grants — The Title II base grant is a formula grant that goes to all 50
states, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands,
and five U.S. Pacific territories. It has two parts. Eighty percent of the award
is based on a state’s proportion of all estimated living AIDS cases, and the
other 20 percent comes from the state’s proportion of AIDS cases within
the state but outside of its EMAs. For states with fewer than 90 AIDS cases,
the minimum grant is $200,000; states with more than 90 cases receive a
minimum of $500,000, and territories receive at least $50,000.
ADAP — About one-third of all Ryan White funding and the majority of
Title II funds—$788 million in FY 2005—is earmarked by Congress for
ADAP. Although ADAP was incorporated in Title II in the original autho-
rization in 1990, the ADAP earmark within the Title II appropriation
started in 1996, with the emergence of HAART. Federal ADAP funds are
distributed according to a formula based on each state’s proportion of
the nation’s living AIDS cases. In addition to the federal grant, some
ADAPs receive state general revenue funding, funds from other parts of
the CARE Act, or funds from negotiated drug rebates from drug manu-
facturers. In 2002, 136,345 clients were served through state ADAPs.36
ADAPs operate in 57 jurisdictions including all 50 states, Puerto Rico, the
District of Columbia, the U.S. Virgin Islands, the Marshall Islands, Guam,
American Samoa, and the Northern Mariana Islands. They primarily pro-
vide FDA-approved prescription drugs to eligible individuals, but they
may also use funds to pay to continue an eligible individual’s private
health insurance if it includes prescription drug coverage. Up to 5 per-
cent and, in some cases, 10 percent of a
state’s ADAP funds may be used to sup-
port programs to help clients adhere to
their drug treatment regimens, which as
mentioned in the treatment section of this
paper is critical for reducing drug resis-
tance and for ensuring treatment efficacy.
States must ensure that an individual
has been medically diagnosed with HIV
and that he or she is considered low-
income as defined by the state to receive
services from ADAP. The statute gives
states flexibility in designing ADAPs,
including establishing income-eligibility
criteria. A few states have set medical
eligibility criteria related to either the
count of CD4+ T cells or the viral load.
Title I (Cities) — Base grants and supplemental grants to
eligible metropolitan areas
Title II (States) — Base grants, ADAP grants, ADAP supple-
mental grants to states, and grants to emerging communities
Title III (Communities) — Grants to public or private
nonprofits to provide early intervention services
Title IV (Communities) — Grants to public or private
nonprofits to serve women, infants, children, and youth
Part F — AIDS Education Training Centers, dental grants,
Special Projects of National Significance
Ryan White CARE Act Structure at a Glance
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Thirty-eight ADAPs provide prescription drugs to individuals with in-
comes at or above 300 percent of the federal poverty level (FPL). 37 (The
FPL, for one person in the contiguous 48 states and District of Colum-
bia, was $9,570 in 2005; 300 percent of the FPL would be $28,710.) Eleven
states set their income levels at 200 percent of the FPL, and North Caro-
lina set its level at 125 percent of the FPL, the lowest of all the states.38
Similarly, the formularies set by ADAPs vary widely; 17 ADAPs do not
provide all FDA-approved antiretrovirals.39
As the payer of last resort for HAART, many state ADAPs have experi-
enced more demand for drugs than they have resources to meet. As of
July 2005, eight states had instituted waiting lists for drugs, with a total
of 435 people on them. In response to growing waiting lists, in June 2004
President Bush authorized one-time, emergency funding of $20 million
to serve people on waiting lists in 10 states. Currently, 1,487 individuals
are enrolled in the emergency program. That funding will expire in Sep-
tember 2005, and those individuals will presumably revert back to their
state’s waiting lists, which will likely increase the total number of indi-
vidual on waiting lists to 1,922 in nine states.40
In this time of continued fiscal belt-tightening among most government
jurisdictions, states are also implementing a variety of cost-containment
strategies in their ADAPs. Arkansas, Missouri, New Hampshire, and Utah
have reduced their formularies, and Oklahoma and South Dakota have
established annual per capita expenditure limits. Nine ADAPs anticipate
instituting new or additional measures before the end of the current ADAP
fiscal year, March 31, 2006.41
The 2000 reauthorization added a supplemental ADAP grant program to
help states with demonstrated severe need to increase access to medica-
tions. Three percent of ADAP funding is reserved for this program, and
states must meet certain eligibility criteria to receive it. States may only
use these funds to purchase drugs and they must match a dollar for every
four federal dollars provided through this program. Not all eligible states
take advantage of this additional money because they cannot come up
with the state match.
Emerging Communities Grants — In an attempt to respond to the grow-
ing epidemic in small urban centers, and in suburban and rural areas, in
the 2000 reauthorization Congress added the emerging communities for-
mula grant program to Title II. It is unclear why Congress placed this
grant program in Title II, which funds states, instead of in Title I, which
funds cities. Funds are distributed to communities with a population of
at least 50,000 that have had between 500 and 1,999 reported AIDS cases
over the last five years. Funding is divided into two tiers, with 50 percent
awarded to communities with 1,000 to 1,999 AIDS cases and 50 percent to
communities with 500 to 999 AIDS cases. Within the two tiers, funds are
distributed to communities based on their proportion of AIDS cases within
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the tier. In FY 2004, four qualifying communities had between 1,000 and
1,999 cases, and 25 communities had between 500 and 999. Unlike Title I
grants to EMAs, funding for emerging communities runs from year to
year, with no guarantee of future funding.
Title II also has a hold harmless provision that applies to the base grant
and ADAP grant programs. If the funding formula would result in a
state’s base grant or ADAP grant declining, the hold harmless provi-
sion would ensure that the award would not decline more than 1 per-
cent per year from the FY 2000 award. The provision is written so that
the base and ADAP awards will never drop below 95 percent of the
state’s FY 2000 appropriation.
Title III (Part C) of the CARE Act
Whereas the first two titles of the Act provide funds to metropolitan ar-
eas and states, the third title awards competitive grants to community-
based organizations that serve people living with HIV/AIDS. Grantees
are public and private nonprofit primary care providers—mostly feder-
ally qualified health centers (FQHCs), city and county health departments,
hemophilia treatment centers, and outpatient facilities at academic medi-
cal centers. Ninety-eight percent of Title III funds are used to provide
early intervention services for uninsured and underinsured individuals.
Early intervention services include counseling, testing, primary care, drug
therapy, case management, and mental health services, among others.
The remaining 2 percent of funds is awarded for capacity building and
planning to enable communities to serve this population more effectively.
The FY 2005 appropriation for this title was $198 million, 10 percent of
total Ryan White funding.
Title IV (Part D) of the CARE Act
Title IV awards competitive grants to public and private nonprofit orga-
nizations to provide primary and specialty care; substance abuse and
mental health services; support services such as transportation, child care,
and housing assistance; care coordination; access to clinical trials and clini-
cal research to HIV-positive women, infants, children, and youth; and
supportive services to family members and others who care for them. A
special focus of Title IV is to identify HIV-positive pregnant women and
ensure that they have access to prenatal care in order to prevent perinatal
transmission of the virus. Congress appropriated $73 million for Title IV
in FY 2005, which is 4 percent of total Ryan White funding.
Part E authorizes grants for emergency response employees and estab-
lishes notification procedures in case of exposure to infectious diseases,
but the corresponding funds have never been appropriated.
Background Paper
August 22, 2005
National Health Policy Forum  |  www.nhpf.org 23
Part F: Provider Training, Dental
Reimbursement, and Special Projects
The 1996 reauthorization added three other grant programs as Part F of
the Act. The AIDS Education and Training Centers (AETC) Program is
the clinical training component of the Act, and it funds a network of 11
regional centers with more than 130 sites that conduct multidisciplinary
training and education programs for health care providers who treat
patients with HIV/AIDS. From June 2002 to June 2003, about 62,000
clinicians were trained in AETCs; the majority (64 percent) were physi-
cians. Other trainees include physician assistants, nurses, nurse practi-
tioners, oral health professionals, pharmacists, and clinical faculty.42 The
AETC appropriation for FY 2005 was $35 million, or 2 percent of total
Ryan White funding.
Early signs of AIDS often manifest in the mouth
through conditions such as thrush, warts, and
gum disease. Maintaining good oral health, good
nutrition, and other healthy lifestyle habits can
reduce the risk of opportunistic infections for an
individual with HIV. The Ryan White dental pro-
gram was created to alleviate significant difficulties in access to dental
care for people living with HIV/AIDS. It was transferred from Title VII
of the Public Health Service Act to Ryan White (Title XXVI) in 1996. The
program reimburses dental schools, postdoctoral dental programs, and,
since the 2000 reauthorization, dental hygiene programs for the uncom-
pensated services they provide to people living with HIV/AIDS. The FY
2005 appropriation for the dental reimbursement program was $13 mil-
lion, or about 0.5 percent of total Ryan White funding.
The Special Projects of National Significance Program (SPNS) supports
the development and replication of innovative models in HIV/AIDS care
and service delivery. SPNS is normally funded by set-asides from Titles I
through IV of at least $20 million but not more than $25 million in any
given fiscal year, but appropriations language for FY 2003–2005 directed
that SPNS be funded from Public Health Service evaluation set-asides
instead. For FY 2005, SPNS was funded at $25 million. Grantee organiza-
tions include academic health center clinics, FQHCs, community-based
organizations, state and local health departments, among others. Grant-
ees test new models of care to find ways to increase treatment effective-
ness for specific populations, such as those living along the U.S.–Mexico
border or in correctional settings, or for improving treatment for those
with comorbidities. HRSA awards grants competitively, and the grants
typically last three to five years (Table 1, see next page).
The steady expansion of people living
with HIV/AIDS increasingly burdens local
care systems and Ryan White as the payer
of last resort.
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POLICY ISSUES FOR REAUTHORIZATION
As with deliberations over past reauthorizations, policymakers must con-
sider the changing HIV/AIDS epidemic and advances in prevention and
treatment when reflecting on the adequacy of the existing statute. They
need to consider what the epidemic will look like over the next five years,
what treatment needs will be, and what might be the CARE Act’s role in
addressing those needs. They cannot ignore that the steady expansion of
people living with HIV/AIDS—the hundreds of thousands not in care, and
the additional 22,000 seeking services each year—increasingly burdens lo-
cal health care systems and Ryan White as the payer of last resort.
Although some state budgets are beginning to show signs of improve-
ment, Medicaid continues to consume an average of nearly 20 percent
of state resources. In response, some states are scaling back provider
TABLE 1
Ryan White CARE Act Federal Appropriations by Title, Fiscal Years 1995–2006
* This does not include an additional $20 million that was appropriated in FY 2004 for emergency funding for ADAPs.
** President’s budget request.
Source: HRSA, “Appropriations History FY 1991 to FY 2005,” table, January 4, 2005, available at ftp://ftp.hrsa.gov/hab/fundinghis04.xls, and HRSA,
Fiscal Year 2006: Justification of Estimates for Appropriations Committees, available at www.hhs.gov/budget/06budget/documents/HRSABudget06.pdf.
millions $
Title II Total
 Fiscal Year Title I (includes ADAP) ADAP Title III Title IV AETC Dental (billions $)
1995 $357 $ 198 N/A $ 52 $26 N/A N/A $0.63
1996 392 261 $ 52 57 29 N/A N/A 0.74
1997 450 417 167 70 36 $16 $ 8 1.00
1998 465 543 286 76 41 17 8 1.15
1999 505 738 461 94 46 20 8 1.41
2000 546 824 528 138 51 27 8 1.60
2001 604 911 589 186 65 32 10 1.81
2002 619 977 639 194 71 35 13 1.91
2003 627 1,067 714 201 75 36 13 2.02
2004 623 1,100 749* 200 74 35 13 2.04
2005 618 1,136 788 198 73 35 13 2.07
 2006** $618 $1,146 $798 $198 $73 $35 $13 $2.08
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payments, income eligibility levels, and benefits—especially pharmaceu-
tical benefits, which put additional pressure on the CARE Act. African
Americans and other minority groups continue to bear a disproportion-
ate disease burden and women, particularly women of color, are increas-
ingly infected with the virus. Preexisting disparities in access to care for
minority populations make treatment financed through Ryan White ever
more needed and ever more challenging to provide.
Most of the reauthorization debate focuses on changes
within the existing four-title structure, but some do ad-
vocate for major restructuring. Assuming maintenance
of the four title structure, key areas of debate include (a)
whether and what changes should be made to allocate
treatment dollars more equitably, (b) whether the statute
needs to be modified to reinforce the shift to a chronic
disease model from a palliative care model by defining a core set of
services, (c) whether there is a congressional role to be played in stabi-
lizing and providing more uniformity to ADAPs, and (d) ways to im-
prove grantee accountability.
Improving Access Equity
Through Funding Allocation Changes
There are a number of issues under debate related to Ryan White funding
formulas. One revolves around the data that goes into the formulas in Titles
I and II. The current statute mandates a shift from using AIDS to HIV data
by FY 2007, but there are questions about the impact and feasibility of such
a switch. Some HIV/AIDS policymakers would like to see other variables
such as uninsurance rates, relative costs of care, public and private insur-
ance coverage, and relative generosity of a state’s Medicaid program in-
cluded in the formula for determining a jurisdiction’s grant award. Others
would like to reduce funding inequities that result from formula design as
well as the hold harmless and grandfathering provisions in Titles I and II.
What’s in a Number? At present, Title I and II formula grants are distrib-
uted on the basis of one measure: relative disease burden, calculated from
AIDS data. By continuing to distribute Ryan White funds on the basis of
AIDS data, the statute ignores the reality that the majority of the HIV/
AIDS population in need of treatment is HIV positive but their disease has
not progressed to AIDS. Using AIDS data instead of HIV data also fails to
compensate jurisdictions for working hard to get HIV-positive people di-
agnosed and into treatment early, thereby preventing their deterioration
from HIV status to AIDS. Many argue that areas with emerging HIV epi-
demics and therefore limited AIDS case history, like the southeastern states,
are underfunded because HIV cases are not counted in the formulas.
There is general consensus that using valid HIV data to distribute Ryan
White dollars would more accurately reflect the nature of the epidemic
and treatment needs, as well as create an additional incentive for states
There is general consensus that
using valid HIV data to distribute
Ryan White dollars would more
accurately reflect the nature of the
epidemic and treatment needs.
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and localities to identify a higher proportion of people infected with HIV.
The debate continues to lie in determining whether FY 2007 is the appro-
priate time for that switch. Concerns about switching from AIDS to HIV
data center on the lack of nationally available comparable HIV data and
the level of maturity and reliability of the HIV data that is collected. As
mentioned earlier in this paper, the CDC accepts only confidential, name-
based reports for inclusion in its national HIV prevalence estimate. Al-
though 38 states currently provide name-based reports to the CDC, the
CDC only uses data from the 32 states that it considers to have mature
data collection systems.
As directed by the 2000 reauthorization, the IOM explored the feasibility
of switching to HIV data. The IOM committee determined that HIV data
was not ready for inclusion at the time of its 2004 report. It made several
recommendations to DHHS and others to either justify the inclusion of
HIV data by FY 2007, as Congress has contemplated, or to conclude that
reported HIV cases do not result in a more equitable resource allocation
and, thus advising Congress that it should reconsider its recommenda-
tion prior to FY 2007.43 On July 27, 2005, the Bush administration released
its principles for Ryan White reauthorization. One of the principles is to
maintain the current statutory requirement that all states must submit
name-based HIV data by FY 2007.44
The Government Accountability Office (GAO) analyzed the impact of
using HIV and AIDS data in distributing Title II base grant funds for FY
2004 and found that incorporating HIV data would result in funding shifts;
about half of the states would experience funding increases (a large por-
tion of those increases would be in the southern states), and half would
experience decreases. Maintaining hold harmless and minimum grant
provisions would significantly mediate these shifts, however. The analy-
sis found that if hold harmless provisions were removed from the modi-
fied formula, about 10 percent, or $28.4 million, of Title II base grants
would shift across states. Twenty-six grantees, including 11 from the South,
would receive funding increases and 26 would receive decreases; Califor-
nia, New York, and Georgia would experience the largest decreases. “States
that would benefit from the use of HIV cases tend to be those with the
oldest HIV case reporting systems. Those states with the oldest systems
include 11 southern states whose HIV reporting systems were imple-
mented prior to 1995.”45 At least initially, maintaining the hold harmless
and minimum grant requirements would result in just a 4 percent shift in
funds instead of the 10 percent shift if they were eliminated.
Many argue that the best way to improve HIV surveillance data is to tie
states’ prevention and treatment funding to reporting name-based data to
the CDC. Such an approach would encourage states to intensify their test-
ing programs to capture their share of the 250,000 to 300,000 people living
with HIV/AIDS that the CDC estimates are currently undiagnosed. Ulti-
mately, policymakers must decide whether the future benefit of improved
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HIV surveillance data is worth the tradeoff of using the imperfect HIV
data currently available and the resulting funding shifts that would oc-
cur. As the GAO study demonstrated, part of that decision requires that
policymakers should recognize that switching to HIV data as a means to
achieve more equitable funding distribution is less meaningful if hold
harmless provisions are kept intact.
Beyond Disease Burden: Measuring Need — Determining resource
needs for a given area requires knowing its disease burden, the costs of
providing care, and the available resources. Currently, the CARE Act’s
formulas rely solely on disease burden to distribute funding. Different
parts of the CARE Act—Title I supplemental grant awards and Title III
and IV awards—attempt to take other factors into account in allocating
funding. The IOM committee that published Measuring What Matters ex-
amined the method for determining severity of need for the Title I supple-
mental grant program, the largest of the Act’s competitive grant programs
in terms of funding. Although the committee’s findings are focused spe-
cifically on the process for this grant program, they are relevant to any
attempt to incorporate other measures, beyond AIDS or HIV data, into
determining need throughout the Act.
The committee found that although HRSA
requests extensive information in the appli-
cation process about the epidemiology of
HIV infection and AIDS, the prevalence of
comorbid conditions, poverty and insur-
ance status, and populations with special
needs, there are no reliable, consistent, and comparable data at a local level
to make the responses meaningful. The committee therefore recommended
that HRSA undergo a consultative process to develop models based on
publicly available data to estimate EMA-level resource needs. They added
that HRSA needs to find a way to measure actual need in a number of areas
to check the estimates generated by the model. In its reauthorization prin-
ciples, the Bush administration recommends providing the Secretary of
DHHS the authority to create a severity of need core services index (SNCSI)
based on objective criteria to distribute funds to the neediest metropolitan
areas and states first. The SNSCI would use data-driven criteria to capture
HIV prevalence, poverty levels, and availability of other local, private, state,
and federal resources. They argue that distributing funds in this way,
coupled with a maintenance of effort requirement, would make the pro-
gram more responsive to populations most in need.46
On the surface, it may seem more equitable to develop such models in an
attempt to distribute resources on the basis of a number of objective mea-
sures of need, not just disease burden, but some policymakers argue that
this process would penalize EMAs and states that have worked hard to
make more resources available by strengthening their safety nets and ex-
panding their Medicaid programs. They question whether such an approach
would create perverse incentives for jurisdictions to invest less in the safety
As currently written, the statute distributes
more funding to states with eligible EMAs than
states without them, regardless of whether the
states have similar total AIDS cases.
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net and Medicaid to qualify for more Ryan White funding. On the other
hand, Ryan White dollars are small in comparison to the federal matching
funds states receive for Medicaid, so if states have expanded Medicaid cov-
erage, less Ryan White funding might not be a significant issue.
Double Counting: Fair Play or Dubious Practice? The current statute
distributes more funding to states with eligible EMAs than states with-
out them, regardless of whether the states have similar total AIDS cases.
The double counting of AIDS cases in EMAs—in the Title I formula and
again for 80 percent of the base grant for Title II—means that states with
similar numbers of AIDS cases but differences in population centers can
receive significantly different funding for each AIDS case, even if they
have a similar number of total AIDS cases. The GAO testified before a
congressional subcommittee to this point in June 2005 and provided the
example of South Carolina and Connecticut. For fiscal year 2004, Con-
necticut had 5,363 AIDS cases and South Carolina had 5,563. “However,
Connecticut had two EMAs that accounted for 91.3 percent of its cases
while South Carolina had none. Connecticut received $26,797,308 ($4,997
per AIDS case) in combined Title I and Title II funding while South Caro-
lina, with 200 more cases, received $20,705,328 ($3,722 per AIDS case).
Connecticut received 29 percent more funding than South Carolina, a dif-
ference of $6,091,980, or $1,275 per AIDS case.”47
Some might argue that the cost of treatment in Connecticut is higher than
South Carolina and therefore the per AIDS case funding discrepancy is
justified, but in the absence of formulas that take treatment cost data into
account, these per-case discrepancies appear unfair. The Bush adminis-
tration has said it will support the elimination of the double counting of
cases between EMAs and states in Titles I and II.48
Harmless to Some; Harmful to Others — The goal of the Title I and II
hold harmless provisions is to minimize the shifts in funding to EMAs
and states from year to year and the service disruptions that might re-
sult. Hold harmless funds are added to an EMA’s formula grant to bring
it up to the level defined in statute (at least 85 percent of its base year
for Title I and 95 percent for Title II). The downside of such provisions is
that they make it difficult for policymakers to distribute funding to ar-
eas most affected by the epidemic. In addition, the money that is set
aside to pay for the hold harmless provision would otherwise be dis-
tributed to eligible grantees.
As written, the current Title I hold harmless provision benefits 21 EMAs,
but San Francisco receives almost 92 percent of the hold harmless dol-
lars ($7,358,239 in FY 2004).49 In San Francisco’s case, hold harmless
dollars represent 45.5 percent of its Title I base grant award.50 The ad-
ministration has stated it supports the elimination of current hold harm-
less provisions altogether.51 Some advocacy groups would prefer a less
drastic change; they recommend changing the Title I hold harmless pro-
vision so that it will provide 79 percent of a jurisdiction’s base year award
instead of the current 85 percent.52
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Ryan White fills the gaps left by Medicaid,
Medicare, private insurance, and state and
community programs, which leads to signifi-
cant variation in access across jurisdictions.
Similarly, in 1996 when the authorizers grandfathered EMAs eligible as of
FY 1996, they limited the program’s future ability to distribute funds to
areas most in need. For example, in FY 2004, 29 of 51 EMAs did not meet
the statutory threshold of 2,000 ELCs within the past five years. Those 29
EMAs reported AIDS cases ranging in number from 223 to 1,941 within the
past five years. This provision creates disparities in per case funding
between grandfathered EMAs in Title I and those smaller urban areas re-
ceiving funds under the emerging communities program in Title II. For
instance Memphis, which receives an emerging community grant, reported
more AIDS cases than 26 grandfathered EMAs.53 About 20 percent of Title I
funding, or $116 million, was directed to these grandfathered EMAs.
Mandating a Set of Core Services: Positive or Punitive?
Community-level decision making and administrative flexibility have
always been at the center of the CARE Act. A second key reauthorization
debate focuses on whether that flexibility should be curtailed by defining
a core set of services and a specific proportion of grant funds to be spent
on those core services in an effort to create more equitable access to treat-
ment across the country. As the funder of last resort, Ryan White is meant
to fill gaps left by Medicaid, Medicare, private insurance, and state and
community programs, which leads to significant variation in access across
states and jurisdictions.
Core services would include primary medical care, medications, labora-
tory tests, oral health, mental health and substance abuse services, case
management, and nutrition and treatment adherence counseling. Accord-
ing to FY 2003 data, about 53 percent of Title I grant funds across all EMAs
were used to provide health care services, 23 percent went to fund sup-
port services, 12 percent for case management, and the remainder for
planning council support and other grant administration. In individual
EMAs, proportions dedicated to health
care services ranged from highs of 79 per-
cent in San Juan, 75 percent in Atlanta, and
70 percent in Denver to lows of 9 percent
in Minneapolis, 23 percent in Oakland,
California, and 27 percent in Boston.54
One analysis funded by HRSA found that for Title I grantees there was no
significant relationship between a jurisdiction’s HIV health care financing
environment (they were deemed low, medium, or high based on Medic-
aid, insurance rates, and other factors) and its Title I health care expendi-
tures. The analyses actually found a slight, nonsignificant trend that the
more resources there were in a health care financing environment, the more
Title I and II funds were spent on health care services.55
In response to this variation, a number of key HIV/AIDS advocacy organi-
zations are recommending mandating a set of core services and funding
set-asides. The AIDS Healthcare Foundation, recommends mandating that
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at least 65 percent of Title I funds be spent on medical services. The HIV
Medicine Association and American Academy of HIV Medicine also sup-
port a core services mandate. They advocate that at least 25 percent of
awards be used for primary medical care services and 25 percent for ba-
sic medical services. The Bush administration also supports defining a
set of core medical services (defined as “basic, primary medical care and
medication”) and wants 75 percent of Ryan White funds across the four
titles to be used for core medical services.56
Other key advocacy groups including the National Alliance of State and
Territorial AIDS Directors (NASTAD), the Communities Advocating
Emergency AIDS Relief (CAEAR) Coalition, and AIDS Action oppose
defining a mandatory set of services or funding set-asides for those ser-
vices.57 They contend that such mandates would prove detrimental in a
number of ways. They argue that
jurisdictions that have created an
adequate health care safety net,
which provides access to primary
care services to the uninsured or
underserved with HIV/AIDS, need maximum flexibility to be able to tar-
get most of their dollars to support services. Such a mandate for medical
services could also have a negative effect in resource-poor areas, where
Ryan White dollars may be the only source of funding for support ser-
vices. These organizations argue that instead of mandating such a prior-
ity, HRSA should exercise greater administrative oversight of grantees to
ensure Ryan White resource allocation complements local capacity.
Can ADAPs Adapt, or Should Congress Help Out?
Access to ADAP pharmaceuticals varies from state to state. Demand for
a state’s ADAP services depends on a number of factors, including the
drug coverage its Medicaid program offers and whether there is a state
pharmacy assistance program in operation. States have the flexibility to
define income eligibility levels and set their formularies. Despite a 15-
fold increase in the national ADAP earmark between FY 1996 and FY
2005, some ADAPs do not have the resources to meet demand and are
implementing waiting lists and cost-containment measures. In light of
this trend, part of the debate around ADAP reauthorization focuses on
finding ways to financially stabilize those ADAPs that are unable to
meet existing demand. At the same time, some in the HIV/AIDS com-
munity advocate a minimum income eligibility standard and standard
formulary as a way to improve access equity across states, but these
changes would prove costly to those ADAPs already experiencing re-
source problems.
In addition to these issues, there is concern that the new Medicare pre-
scription drug benefit, due to begin on January 1, 2006, may negatively
affect some ADAPs. Most Medicare beneficiaries with HIV/AIDS are
Despite a 15-fold increase in the national ADAP ear-
mark over the last 10 years, some ADAPs cannot
meet demand and are implementing waiting lists.
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dually eligible for Medicaid and will receive a low-income subsidy or
“extra help” from the government to pay for premiums, deductibles,
coinsurance, and any gaps in coverage under the new benefit. The esti-
mated 35 percent of Medicare beneficiaries with HIV/AIDS who are
not dual eligibles, however, will have to pay $3,600 in out-of-pocket
costs (such as deductibles, monthly premiums, coinsurance) before
Medicare catastrophic drug coverage begins. If a beneficiary needs help
paying premiums, deductibles, or other cost sharing, any contribution
made by an ADAP toward those costs would not count toward the
beneficiary’s true out-of-pocket costs. Unless the beneficiary could pay
for these costs him or herself, catastrophic coverage would never be
triggered, leaving the beneficiary in a coverage gap and responsible for
100 percent of their drug costs. At this point they would likely return to
ADAPs as their source for prescription drugs again.58
In terms of improving the programs’ financial status, ADAPs are cur-
rently eligible to receive significant discounts on prescription drugs
through the federal “340B” drug discount program. As of June 2004, 51 of
57 ADAPs participated in the 340B program. One suggested way to in-
crease ADAPs’ purchasing power beyond that of the 340B program is to
extend to ADAPs the federal ceiling price that is currently given by drug
manufacturers to the Department of Veterans Affairs, Department of De-
fense, PHS, and the Coast Guard. NASTAD, the CAEAR Coalition, and
AIDS Action support this option. Among other ways to stabilize ADAPs,
the Bush administration recommends giving the Secretary of DHHS the
authority to redistribute any Title I and II funds unspent by grantees to
state ADAPs with the greatest need. Others have suggested that ADAPs
could collect significant revenues by consistently collecting income-based
fees as outlined in the statute.59
Aside from funding of ADAPs specifically, issues of core formularies
and standardized income eligibility levels remain debatable. The Bush
administration supports giving the Secretary the authority to develop a
list of core medications based on the PHS HIV/AIDS Clinical Practice
Guidelines that would be the priority for federal funding, but it does
not recommend a minimum income eligibility level.60 AIDS Action sup-
ports setting a minimum income eligibility level of 350 percent of the
FPL and establishing an open formulary. The HIV Medicine Associa-
tion, the American Academy of HIV Medicine, and the Southern AIDS
Coalition recommend setting an income eligibility floor at 300 percent
of the FPL. 61 NASTAD opposes any core formulary requirement or mini-
mum income eligibility level; it argues that setting a standard formu-
lary might actually reduce access by creating a formulary ceiling above
which more generous states might not continue to go. (NASTAD also
asserts that states might redirect state revenues to other areas, instead.)
Defining a core formulary would also place financial strains on those
states with leaner formularies, perhaps forcing them to redirect their
Title II base awards to bring their ADAPs into compliance.
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Spotlight on Accountability
The Bush administration has put forth a number of recommendations
focused on improving accountability for Ryan White resources. They in-
clude improving grantee reporting of system and client-level data and
strengthening the payer of last resort role by conducting regular audits.62
The DHHS Office of the Inspector General found in a 2004 report that
Ryan White Title I and II grantees’ monitoring of their subgrantees was
limited and could be improved through guidance from HRSA.63 NASTAD
cautions against mandating any one-size-fits-all approaches to monitor-
ing grantees. It supports increased data sharing between Medicaid and
Medicare with ADAPs to ensure that ADAP funds only pay for drugs
when no other coverage is available.64
Starting from Scratch:
Scrapping the Existing Title Structure
A small but vocal minority argue that the existing title structure should
be done away with completely and that the authorizers should create
an entirely new program. One suggestion would be to direct all fund-
ing to states in two streams—one for medical and support services and
the other for drug assistance—allowing states to set priorities and dis-
tribute funds. Along this line, the AIDS Healthcare Foundation has pro-
posed streamlining the Act into two programs: one for services and one
for drugs, with grants available to cities and to states. They argue that
reducing the title structure to two would improve coordination across
grantees and reduce administrative costs. Supporters of maintaining
the current title structure argue that such changes would create major
dislocations in funding,  which could lead to discontinuity in services
for many people living with HIV/AIDS.
CONCLUSION
Many people with HIV/AIDS who are able to access HAART are living longer,
more productive lives. With somewhere between 40 and 60 percent of people
with HIV/AIDS not receiving regular treatment and an estimated 22,000
new people with HIV in need of services each year, pressure continues to
mount on safety net programs that serve or are designed for people with
HIV/AIDS, like Medicaid and the Ryan White CARE Act. Policymakers have
the difficult task of balancing the policy goal of providing equitable access to
treatment for low-income, uninsured people living with HIV/AIDS across
the country with the reality of finite resources, 15 years of funding history,
and the voices of a variety of interest groups.
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